Earnings Preview: Boston Scientific - Analyst Blog
October 18 2011 - 10:45AM
Zacks
Boston
Scientific (BSX) is scheduled to release its third
quarter fiscal 2011 earnings on Thursday, October 20, 2011 before
the market opens. The company is expected to report EPS of 8 cents
on revenue of $1.908 billion for the quarter, according to the
Zacks Consensus Estimate. For the third quarter of fiscal 2011,
Boston Scientific expects to report adjusted EPS of 6–9 cents on
revenue of $1.87−$1.97 billion.
Previous Quarter
Highlights
Boston Scientific reported an
adjusted (other than amortization expense) EPS of 12 cents during
the second quarter of fiscal 2011, beating the Zacks Consensus
Estimate of 8 cents and the year-ago quarter’s 6 cents.
Revenues increased 2.4% year over
year to $1.975 billion during the quarter, surpassing the Zacks
Consensus Estimate of $1.936 billion. However, excluding the impact
of foreign currency and sales from divested businesses, net sales
remained unchanged.
The company also announced a
restructuring program to increase productivity through zero-based
budgeting and Emerging Market Initiative. In addition, Boston
Scientific announced a $1 billion share repurchase program.
Boston Scientific also updated its
guidance for fiscal 2011. The company expects revenue and adjusted
EPS in the range of $7.675−$7.875 billion (previous guidance of
$7.6−$7.9 billion) and 41−47 cents (34-44 cents), respectively.
Agreement of
Analysts
Estimate revision trends among the
analysts for the second quarter have been insignificant. Over the
last 30 days, out of 22 analysts covering the stock, only 1 lowered
the estimate for the quarter with none moving in the opposite
direction. The analysts have adopted a cautious stance on the
company given the issues witnessed by the core businesses and the
current economic uncertainties.
The Cardiac Rhythm Management (CRM)
market in the US, which declined in high single digits during the
most recent quarter, continues to be the primary area of concern.
This segment has been affected by physician reaction to a study
result published by the Journal of the American Medical Association
regarding evidence-based guidelines for ICD implants, US Department
of Justice’s investigation into hospitals' ICD implants and the
ongoing physician alignment to hospitals and competitive pricing
pressures.
However, the company has adopted a
restructuring program to strengthen its operational effectiveness,
increase competitiveness and support new investments. This program
is expected to reduce annual pre-tax operating expenses by
$225–$275 million exiting 2013, a part of which will be invested in
the business to drive growth ahead. About $155–$210 million (of
which $5–$10 million should be non-cash) of pre-tax charges will be
incurred by the company due to this program, with $10 million
forecast for the third quarter.
Having established a strong
foothold in the US and Europe, Boston Scientific is looking at
establishing its presence in the emerging markets. With only 3–4%
of market share in India, Boston Scientific is aiming for a bigger
pie on the back of Promus Element and Taxus Element launches in
February this year. The company also launched Promus Element in
China this week. We expect an update from the company regarding its
emerging market initiatives.
Magnitude of Estimate
Revisions
For the third quarter, estimates
have remained unchanged at 8 cents over the last 7 and 30 days. For
fiscal 2011 as well, the consensus estimate remained static at 45
cents per share over the past 1 month.
Our
Recommendation
Boston Scientific continues to
focus on strategic initiatives to drive growth and profitability.
Moreover, the company is working on strengthening its portfolio and
targeting suitable acquisitions in areas of unmet medical needs.
The restructuring initiatives undertaken should also lead to
improvement in the bottom line. The stock retains a Zacks # 2 Rank
(Buy) in the short term.
However, we continue to remain
concerned about its core business where the company is witnessing
significant pricing pressure and loss of market share. Besides,
economic uncertainty is impacting procedure volume. The company
also faces stiff competition from players such as
Medtronic (MDT) and St Jude
Medical (STJ). Longer term, we have a Neutral
recommendation on the stock, in line with both its peers.
BOSTON SCIENTIF (BSX): Free Stock Analysis Report
MEDTRONIC (MDT): Free Stock Analysis Report
ST JUDE MEDICAL (STJ): Free Stock Analysis Report
Zacks Investment Research
SJM (NYSE:STJ)
Historical Stock Chart
From May 2024 to Jun 2024
SJM (NYSE:STJ)
Historical Stock Chart
From Jun 2023 to Jun 2024